The Promise and Peril of Crispr
By John Lauerman and Caroline Chen,
Bloomberg Businessweek
| 06. 25. 2015
Untitled Document
Tracy Antonelli and her three daughters suffer from thalassemia, a blood disorder that saps their strength, leaves them anemic, and requires them to visit Boston Children’s Hospital every three weeks for transfusions. “We’re lucky we have a treatment regimen that’s available to us, but it’s cumbersome,” Antonelli says.
A technology in development at several drug companies offers some hope for a more effective and convenient treatment for the Antonellis, and patients with other serious genetic conditions, such as sickle cell anemia. The technique is called Crispr, which stands for clustered regularly interspaced short palindromic repeats. Crispr, a method for editing the human genome—the complete set of an individual’s genetic material present in any of her cells—allows scientists to cut out faulty sections of DNA that can lead to serious illnesses and replace them with healthy ones. In the two-part process, first an RNA “guide” molecule locates the part of the DNA that needs to be removed or fixed. Then a Cas9 protein attaches to the DNA and cuts out the mutation. In some cases, scientists can then insert...
Related Articles
By Marianne Lamers, NEMO Kennislink [cites CGS' Katie Hasson] | 09.23.2025
Een rijtje gespreide vulva’s gaapt de bezoeker aan. Zó ziet een bevalling eruit, en zó een baarmoeder met foetus. Een zwangerschap, maar dan zonder zwangere vrouw, gestript van zorgen, gêne en pijn. De zwangerschapsmodellen en oefenbekkens, te zien in de...
By Auriane Polge, Science & Vie [cites CGS' Katie Hasson] | 09.19.2025
L’idée de pouvoir choisir certaines caractéristiques de son futur enfant a longtemps relevé de la science-fiction ou du débat éthique. Aujourd’hui, les technologies de séquençage et les algorithmes d’analyse génétique repoussent les limites de ce qui semblait encore impossible. Au croisement...
By Charmayne Allison, ABC News | 09.21.2025
It has been seven years since Chinese biophysicist He Jiankui made an announcement that shocked the world's scientists.
He had made the world's first gene-edited babies.
Through rewriting DNA in twin girls' embryos, the man who would later be dubbed...
By Natalie Ram, Anya E. R. Prince, Jessica L. Roberts, Dov Fox, and Kayte Spector-Bagdady, Science | 09.11.2025
After declaring bankruptcy in March 2025, direct-to-consumer (DTC) genetic testing company 23andMe sold the data of more than 15 million people around the world to TTAM Research Institute, a nonprofit organization created by 23andMe’s founder and long-time CEO. 23andMe’s customers...